Squamous Cell Carcinoma of the Head and Neck | Current Treatment: Physician Insights | US | 2020
Immune checkpoint inhibitors have transformed the treatment algorithm for recurrent or metastatic non-nasopharyngeal squamous cell carcinoma of the head and neck (SCCHN) and diversified treatment options beyond standard Erbitux-based regimens. Merck & Co.’s Keytruda and Bristol-Myers Squibb’s Opdivo are already entrenched and good therapeutic options for previously treated recurrent or metastatic SCCHN. The 2019 label expansion of Merck & Co.’s Keytruda has revolutionized the choice of first-line therapy for SCCHN by offering better targeted therapeutic options with Keytruda regimens based on patient characteristics such as PD-L1 expression. The possibility of using immunotherapy with Keytruda frontline will shift current treatment practices.
Questions Answered
- What are the drug-treatment rates in the clinically and commercially relevant SCCHN patient populations?
- How are the immune checkpoint inhibitors performing in the face of existing and established therapies such as Erbitux and standard chemotherapy for recurrent or metastatic disease, according to U.S. medical oncologists?
- What are the patient shares of key therapies used to treat locoregionally advanced non-nasopharyngeal SCCHN and recurrent or metastatic non-nasopharyngeal SCCHN in all lines of therapy?
- What are the main drivers of and obstacles to prescribing current therapies for recurrent or metastatic non-nasopharyngeal SCCHN?
Product Description
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.
